1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Summit's Lead Antimicrobial Fails Pivotal Study, May Spark Therapeutic Shift

Stock Down 50%

 
• By Ayisha Sharma

Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.

CDI Affects Around 50,000 People In The Us Every Year • Source: Alamy

Summit Therapeutics plc’ lead antimicrobial asset has flunked a Phase III study, leading some analysts to predict a second turnaround in therapeutic focus after the company’s mid-stage DMD study failed a few years ago.

The firm’s C. difficile infection (CDI) candidate ridinilazole failed to show superiority over a comparator in the Ri-CoDIFy 2 study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint

 
• By Mandy Jackson

The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Pipeline Watch: Five Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.